BRIEF published on 09/19/2025 at 18:05, 8 months 2 days ago Advicenne : Résultats semestriels en 2025 et perspectives Chiffre D'affaires Résultats Financiers Perspectives États-Unis Sibnayal®
PRESS RELEASE published on 09/19/2025 at 18:00, 8 months 2 days ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne présente ses résultats financiers semestriels au 30 juin 2025 et fait le point sur ses activités. Augmentation du chiffre d'affaires et perspectives favorables avec Sibnayal® Résultats Financiers Croissance Perspectives Advicenne Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 9 months 24 days ago Advicenne obtient l'autorisation de mise sur le marché de Sibnayal® en Arabie saoudite Arabie Saoudite Remboursement Advicenne ATRd Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 9 months 24 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 24 days ago Informations privilégiées / Autres communiqués Advicenne obtient l’AMM et le remboursement de Sibnayal en Arabie Saoudite pour le traitement des maladies rénales rares. Collaboration avec Taïba Healthcare Arabie Saoudite Advicenne Maladies Rénales Rares AMM Sibnayal
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 24 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 9 months 27 days ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
BRIEF published on 07/25/2025 at 07:35, 9 months 27 days ago Advicenne Annonce une Croissance de 9% de son Chiffre d'Affaires pour le S1 2025 Chiffre D'affaires Croissance Advicenne Sibnayal® Marchés Pharmaceutiques
PRESS RELEASE published on 07/25/2025 at 07:30, 9 months 27 days ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
PRESS RELEASE published on 07/25/2025 at 07:30, 9 months 27 days ago Informations privilégiées / Autres communiqués Advicenne publie un chiffre d'affaires en hausse de 9% au S1 2025, avec des ventes de Sibnayal® en progression de 17%. La société dispose de trésorerie jusqu'au 3ème trimestre 2026 Chiffre D'affaires Trésorerie Advicenne S1 2025 Sibnayal®
Published on 05/21/2026 at 23:00, 4 hours 19 minutes ago Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 4 hours 19 minutes ago Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 4 hours 19 minutes ago Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 5 hours 4 minutes ago Linear Announces Acquisition, Share Consolidation and Private Placement
Published on 05/22/2026 at 03:05, 13 minutes ago BAI Capital Announces First Close of New US$800 Million Fund, Continues to Back Asia Growth and Globalization Opportunities
Published on 05/22/2026 at 02:40, 38 minutes ago ESENTIA Completes US $2 Billion Investment-Grade Bond Offering, Achieving Simultaneous Triple-Agency Rating on Inaugural Corporate Bond
Published on 05/21/2026 at 21:45, 5 hours 33 minutes ago Rendeavour becomes the African Continental Free Trade Area's inaugural implementation partner for African industrialisation and trade infrastructure
Published on 05/21/2026 at 20:10, 7 hours 8 minutes ago Ernst Russ AG Divests MV 'EF Emira' and Raises Full-Year 2026 Guidance
Published on 05/21/2026 at 20:05, 7 hours 13 minutes ago EQS-Adhoc: Ernst Russ AG: Upward revision of the guidance for the financial year 2026
Published on 05/21/2026 at 17:45, 9 hours 34 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 9 hours 34 minutes ago CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 16:35, 10 hours 43 minutes ago 260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026
